Internet-delivered CBT for Children With Functional Gastrointestinal Disorders - an Open Pilot Study

Karolinska Institutet31 enrolled

Overview

This pilot-study aims to evaluate the effect size and feasibility of internet-delivered cognitive behavior therapy (ICBT) for children (age 8-12 years) with pain-predominant functional gastrointestinal disorders (e.g. irritable bowel syndrome, functional abdominal pain and functional dyspepsia according to the Rome III criteria). The main component investigated in this study is exposure for gastrointestinal symptoms and for feared stimuli and situations. Children will participate along with one of their parents in the treatment. The parents will also receive specific modules with information on how to support their child in the treatment.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Functional Gastrointestinal Disorders

Interventions

The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.

Eligibility

Sex: ALLMin age: 8 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Children between 8-12 years (until their 13th birthday) who have been diagnosed with any of the diagnoses irritable bowel syndrome, functional dyspepsia or functional abdominal pain according to the Rome III criteria. * Any psychopharmacological medication should be stable since 1 month. * Parents and children need to master Swedish, have access to a computer with internet access, and be willing to participate in 10 weeks of treatment with homework. Exclusion Criteria: * Simultaneous presence of serious somatic disease and / or if the child meets the criteria for other organic disease which better explains the symptoms. * Psychiatric or social problems that are considered serious and in need of a more intense treatment than ICBT leads to exclusion. Children with higher school absenteeism than 40% will not be included. Neither will children who have an ongoing psychological treatment be included,

Locations (2)

Child and Adolescent Psychiatry in Stockholm

Stockholm, Stockholms Lans Landsting, Sweden

Child and Adolescent Psychiatry in Stockholm

Stockholm, Sweden

Outcomes

Primary Outcomes

PedsQL Gastro

Change in gastrointestinal symptoms measured with a self-rating scale from baseline to 10 weeks, and from baseline to 9 months for analysis of effect.

Time frame: Baseline to 10 weeks, baseline to 9 months

Secondary Outcomes

Faces Pain Rating Scale. (FACES)

Change in pain intensity measured with a self-rating scale daily during 2 weeks at baseline and daily during 2 weeks after 9 months for analysis of effect.The Faces Pain Scale is a self-report measure used to assess the intensity of children's pain. Faces have four faces representing least pain and most pain on equal intervals on a scale from 0-10. Its validity is supported by a strong positive correlation (r=0.93, N=76) with a visual analogue scale (VAS) measure in children aged 5-12 years. The metric for scoring (0-10) conforms closely to a linear interval scale.

Time frame: Baseline to 10 weeks, baseline to 9 months

Faces Pain Rating Scale. (FACES)

Change in pain intensity measured with a self-rating scale weekly during treatment for mediation analyses.

Time frame: Weekly during treatment (treatment week 1-9)

The Pain App

Change in pain intensity and daily frequency reported daily during two weeks at baseline, after treatment and at 9 months with a mobile phone application developed by the research group.

Time frame: Baseline to 10 weeks, baseline to 9 months

Pediatric Quality of Life Inventory (PedsQL)

Change in quality of life from baseline to 10 weeks, baseline to 9 months measured with a self-report scale that measures quality of life in adolescents. PedsQL Generic Core scales is a 23-item scale ranging from 0 (never) to 4 (almost always). The PedsQL is shown to distinguish between healthy children and adolescents and pediatric patients with acute or chronic health conditions and demonstrate acceptable reliability and validity.

Time frame: Baseline to 10 weeks, baseline to 9 months

Children´s Somatization Inventory (CSI 24)

Change in inner symptoms from baseline to 10 weeks, baseline to 9 months, measured with a self-report scale that measures inner symptoms (e.g., headache, nausea, heart racing) that often, but not necessarily, occur in the absence of identified disease, in children and adolescents. CSI-24 is a 24-item scale ranging from ranging from 0 '(not at all) to 4 (a whole lot).

Time frame: Baseline to 10 weeks, baseline to 9 months

Functional Disability Index (FDI)

Change in school attendance from baseline to 10 weeks, baseline to 9 months measured with 2 items from a self-report scale that measures school attendance.

Time frame: Baseline to 10 weeks, baseline to 9 months

Insomnia Severity Index (ISI)

Change in problematic sleeping patterns from baseline to 10 weeks, baseline to 9 months measured with a self-report scale that measures sleeping habits.

Time frame: Baseline to 10 weeks, baseline to 9 months

IBS-behavioral responses questionnaire (IBS-BRQ)

Change in Gastrointestinal symptom-specific behaviors measured with a self-rating scale weekly during treatment for mediation analyses, and from baseline to 10 weeks, baseline to 9 months, for analysis of effect.

Time frame: Baseline to 10 weeks, baseline to 9 months

Spence Children Anxiety Scale - short version (SCAS)

Change in anxiety symptoms from baseline to 10 weeks, baseline to 9 months with a self-report scale that measures anxiety symptoms in children and adolescents.

Time frame: Baseline to 10 weeks, baseline to 9 months

Child Depression Inventory - short version (CDI-S)

Change in level of depression from baseline to 10 weeks and from baseline to 9 months measured with a self-report scale that measures depression in children and adolescents.

Time frame: Baseline to 10 weeks, baseline to 9 months

Pain Response Inventory (PRI) - subscale Coping

Change in pain coping from baseline to 10 weeks and from baseline to 9 months measured with a self-report scale that measures pain coping strategies.

Time frame: Baseline to 10 weeks, baseline to 9 months

Pressure Activation Stress Scale (PAS)

Change in stress levels från baseline to 10 weeks and från baseline to 9 months measured with a self-report scale that measures perceived stress. The PAS is developed for children and validated for the age group.

Time frame: Baseline to 10 weeks, baseline to 9 months

Visceral Sensitivity Index (IBS-VSI)

Change in visceral sensitivity from baseline to 10 weeks, baseline to 9 months measured with a self-report scale that measures gastrointestinal symptom-specific anxiety.

Time frame: Baseline to 10 weeks, baseline to 9 months

Client satisfactory questionnaire (CSQ)

Self-rating scale that measures satisfaction with treatment after completion.

Time frame: At 10 weeks

Subjective Assessment Questionnaire (SAQ)

Self-rating scale that measures subjective change in symptoms as an effect of treatment.

Time frame: At 10 weeks

PedsQL Gastro

Change in gastrointestinal symptoms measured with a self-rating scale weekly during treatment for mediation analyses.

Time frame: Weekly during treatment (treatment week 1-9)

IBS-behavioral responses questionnaire (IBS-BRQ)

Change in gastrointestinal symptoms-specific behavior measured with a self-rating scale weekly during treatment for mediation analyses.

Time frame: Weekly during treatment (treatment week 1-9)

ROME-III Questionnaire

Change in children's functional gastrointestinal disorders diagnostic status measured by ROME-III as a self-rating scale.

Time frame: Baseline to 10 weeks, baseline to 9 months

Adverse Events (AE)

Self-rating scale that measures adverse events related to treatment.

Time frame: At 10 weeks

Generalized Anxiety Disorder Screener (GAD-7)

Change in anxiety levels in parents from baseline to 10 weeks, baseline to 9 months measured with a self-report scale that measures anxiety symptoms. GAD-7 is a 7-item scale ranging from 0 (not at all) to 3 (almost every day). Evidence supports reliability and validity of the GAD-7 as a measure of anxiety in the general population.

Time frame: Baseline to 10 weeks, baseline to 9 months

Patient Health Questionnaire (PHQ 9)

Change in depression levels in parents from baseline to 10 weeks, baseline to 9 months measured with a self-report scale that measures depression. PHQ-9 is shown to be a reliable and valid measure of depression severity in adults.

Time frame: Baseline to 10 weeks, baseline to 9 months

Adult Responses to Children's Symptoms (ARCS)

Change in parents responses to their children's abdominal pain from baseline to 10 weeks, baseline to 9 months measured with a self-report scale assessing protectiveness, minimizing, and encouraging responses to children's pain behavior.

Time frame: Baseline to 10 weeks, baseline to 9 months

Parental Behavior in Response to Children's Functional Gastrointestinal Disorders

Change in parental behavior from baseline to 10 weeks, baseline to 9 months measured with a self-report scale assessing common responses to children´s gastrointestinal symptoms.

Time frame: Baseline to 10 weeks, baseline to 9 months

Parental Behavior in Response to Children's Functional Gastrointestinal Disorders

Change in parental behavior measured weekly with a self-report scale assessing common responses to children´s gastrointestinal symptoms.

Time frame: Weekly during treatment (treatment week 1-9)